References
- Walters EH, Reid D, Soltani A, Ward C. Angiogenesis: a potentially critical part of remodelling in chronic airway diseases? Pharmacol. Ther.118(1), 128–137 (2008).
- D’Souza AO, Smith MJ, Miller LA, Kavookjian J. An appraisal of pharmacoeconomic evidence of maintenance therapy for COPD. Chest129(6), 1693–1708 (2006).
- Villetti G, Bergamaschi M, Bassani F et al. Pharmacological assessment of the duration of action of glycopyrrolate vs tiotropium and ipratropium in guinea-pig and human airways. Br. J. Pharmacol.148(3), 291–298 (2006).
- Pak O, Aldashev A, Welsh D, Peacock A. The effects of hypoxia on the cells of the pulmonary vasculature. Eur. Respir. J.30(2), 364–372 (2007).
- Calabrese C, Bocchino V, Vatrella A et al. Evidence of angiogenesis in bronchial biopsies of smokers with and without airway obstruction. Respir. Med.100(8), 1415–1422 (2006).
- Nichols J. Combination inhaled bronchodilator therapy in the management of chronic obstructive pulmonary disease. Pharmacotherapy27(3), 447–454 (2007).
- Richter K, Stenglein S, Mucke M et al. Onset and duration of action of formoterol and tiotropium in patients with moderate to severe COPD. Respiration73(4), 414–419 (2006).
- van Noord JA, Aumann JL, Janssens E et al. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest129(3), 509–517 (2006).
- Mapel DW, Nelson LS, Lydick E, Soriano J, Yood MU, Davis KJ. Survival among COPD patients using fluticasone/salmeterol in combination versus other inhaled steroids and bronchodilators alone. COPD4(2), 127–134 (2007).
- Joppa P, Petrasova D, Stancak B, Tkacova R. Systemic inflammation in patients with COPD and pulmonary hypertension. Chest130(2), 326–333 (2006).
- Sin D, Man SFP. Is systemic inflammation responsible for pulmonary hypertension in COPD? Chest130(2), 310–312 (2006).
- Zhao H, Zhao X, Bai CX, Wang XD. Potentials of interorgan signals in the development of pancreatitis-associated acute lung injury and acute respiratory distress syndrome. J. Organ Dysfunction1, 32–44 (2005).
- Fitzgerald MF, Fox JC. Emerging trends in the therapy of COPD: novel anti-inflammatory agents in clinical development. Drug Discov. Today12(11–12), 479–486 (2007).
- Wright JL, Tai H, Wang R, Wang X, Churg A. Cigarette smoke upregulates pulmonary vascular matrix metalloproteinases via TNF-α signaling. Am. J. Physiol. Lung Cell. Mol. Physiol.292(1), L125–L133 (2007).
- Perlstein TS, Lee RT. Smoking, metalloproteinases, and vascular disease. Arterioscler. Thromb. Vasc. Biol.26(2), 250–256 (2006).
- Churg A, Cosio M, Wright JL. Mechanisms of cigarette smoke-induced COPD: insights from animal models. Am. J. Physiol. Lung Cell. Mol. Physiol.294(4), L612–L631 (2008).
- Sun B, Li H, Shakur Y et al. Role of phosphodiesterase type 3A and 3B in regulating platelet and cardiac function using subtype-selective knockout mice. Cell. Signal.19(8), 1765–1771 (2007).
- Rennard SI, Fogarty C, Kelsen S et al. The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med.175(9), 926–934 (2007).
- Bozinovski S, Hutchinson A, Thompson M et al. Serum amyloid a is a biomarker of acute exacerbations of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med.177(3), 269–278 (2008).
- Sverzellati N, Molinari F, Pirronti T et al. New insights on COPD imaging via CT and MRI. Int. J. Chron. Obstruct. Pulmon. Dis.2(3), 301–312 (2007).
- Vlahos R, Bozinovski S, Hamilton JA, Anderson GP. Therapeutic potential of treating chronic obstructive pulmonary disease (COPD) by neutralising granulocyte macrophage-colony stimulating factor (GM-CSF). Pharmacol. Ther.112(1), 106–115 (2006).
- Peifer C, Wagner G, Laufer S. New approaches to the treatment of inflammatory disorders small molecule inhibitors of p38 MAP kinase. Curr. Top. Med. Chem.6(2), 113–149 (2006).
- Zhang J, Shen B, Lin A. Novel strategies for inhibition of the p38 MAPK pathway. Trends Pharmacol. Sci.28(6), 286–295 (2007).
- Rommel C, Camps M, Ji H. PI3K δ and PI3K γ partners in crime in inflammation in rheumatoid arthritis and beyond? Nat. Rev. Immunol.7(3), 191–201 (2007).